Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 15/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 15/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770580 | 0.90 | CDC7 (0.47) | CDC7DBF4KDM4EPOLBKMT2A | |
| SCHEMBL5774853 | 0.89 | TRPM8 (0.43) | KDM4EPOLBMAPK14MAPK1KMT2A | |
| SCHEMBL5773483 | 0.82 | KDM4E (0.51) | KDM4EMAPK1KMT2AL3MBTL1 | |
| SCHEMBL5873216 | 0.80 | KDM4E (0.41) | KDM4EMAPK1KMT2AL3MBTL1 | |
| SCHEMBL5775974 | 0.80 | ATAD2 (0.40) | CDC7DBF4KDM4EL3MBTL1 | |
| SCHEMBL5872933 | 0.79 | KDM4E (0.41) | KDM4EMAPK1L3MBTL1 | |
| SCHEMBL5872907 | 0.79 | RPA1 (0.44) | KDM4EMAPK1 | |
| SCHEMBL5873062 | 0.78 | CDC7 (0.47) | CDC7DBF4KDM4EPOLBKMT2A | |
| SCHEMBL5768711 | 0.77 | L3MBTL1 (0.42) | KDM4EKMT2AL3MBTL1 | |
| SCHEMBL5747881 | 0.76 | KDM4E (0.45) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | CDC7 120/4885DBF4 1446/4885KDM4E 2869/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | CDC7 120/4885DBF4 1446/4885KDM4E 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.